Replies to post #162630 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Lykiri,

I believe the Germans took microarray to the next level and used it for specific cell maturation/activation characteristic selection. I believe NWBO handed the Germans the microarray type they wanted. Then the chip technology was used to isolate and gather DCs with specific characteristics from a naturally heterogeneous matured and or matured/activated DC population. Then I believe NWBO essentially cloned those cells and reintroduced them to the rest of the DC mix in a way that makes more treatments out of the same amount of tumor lysate. This process perhaps creates a reduced need for multiple leukopheresis procedures.

So in review there could be improved safety from a more closed system process with tangential flow filtration which also helps prevent unwanted activation. Then there could be safety from German chip technology which leads to less need for multiple leukopheresis and improves DC mix and effectiveness. Finally there is apparent safety with no differences in patient adverse events from these changes (equivalency). To top it off, all this is happening while Linda Powers essentially states in the recent ASM that patients are living longer (eventing slower) than they were expecting which indicates in a 10 year old trial that an "unexpected" change to a slower event rate happened perhaps right when they thought they might speed the trial up with lowered inclusion criteria. Best wishes.